Ophthalmology Panel
The Ophthalmology Genetics Panel is a targeted Next-Generation Sequencing (NGS) assay engineered to comprehensively profile germline mutations across genes governing ocular structure, photoreceptor function, corneal/lens clarity, ocular pigmentation, and optic nerve transmission. Ocular disorders encompass a vast, clinically overlapping spectrum including inherited retinal dystrophies, anterior segment dysgenesis, early-onset glaucoma, congenital cataracts, and optic neuropathies. This panel resolves diagnostic ambiguity in complex ophthalmic cases, enabling accurate molecular diagnosis, eligibility assessment for gene therapies, longitudinal vision preservation management, and family risk stratification.
Key Features & Advantages
- Definitive Molecular Diagnosis: Resolves phenotypic overlap and diagnostic complexity across inherited eye diseases (e.g., differentiating subtypes of Retinitis Pigmentosa or macular dystrophies).
- Eligibility for Gene Therapies: Identifies candidates for approved gene therapies (e.g., Luxturna for bi-allelic RPE65-mediated retinal dystrophy) and emerging clinical trial pipelines.
- Early Detection of Syndromic Conditions: Differentiates isolated ocular phenotypes from complex systemic syndromes (e.g., Usher, Bardet-Biedl, Alport syndromes) prior to the onset of renal, auditory, or neurological impairment.
- Cascade Screening & Family Planning: Establishes precise inheritance modes (autosomal dominant/recessive, X-linked, or mitochondrial) to guide carrier testing, PGT-M, and prenatal options.
Ophthalmology NGS Panel vs. Conventional Ophthalmic Testing
| Feature | Ophthalmology Genetics Panel (NGS) | Standard Ophthalmic Diagnostics (ERG, OCT, Visual Field, Slit-Lamp) |
| Diagnostic Scope | Genes encoding photoreceptors, structural, and optic proteins | Retinal layer thickness, intraocular pressure, and electrical response |
| Etiological Resolution | High (Pinpoints the specific causative genetic mutation) | Phenotypic (Detects functional or structural damage, not root cause) |
| Pre-Symptomatic Detection | Yes (Identifies risk prior to photoreceptor degeneration) | No (Detects changes only after cellular or structural damage occurs) |
| Targeted Therapeutics | Directs gene replacement therapy and gene-specific interventions | Symptomatic, surgical, or supportive ocular pressure management |
| Syndromic Prognosis | High (Predicts extra-ocular organ risks like hearing or renal loss) | None |
Key Applications
- Inherited Retinal Dystrophies (IRD): Retinitis Pigmentosa (RP), Leber Congenital Amaurosis (LCA), Stargardt Disease, Cone-Rod Dystrophy, and Choroideremia.
- Optic Neuropathies & Atrophies: Leber Hereditary Optic Neuropathy (LHON) and Autosomal Dominant Optic Atrophy (OPA1).
- Anterior Segment & Lens Disorders: Congenital Cataracts, Corneal Dystrophies, Aniridia (PAX6), and Anterior Segment Dysgenesis.
- Early-Onset Glaucoma: Congenital and Juvenile Glaucoma (MYOC, CYP1B1, OPTN).
- Ocular Albinism & Nystagmus: Genetic evaluation of hypopigmentation and congenital involuntary eye movement disorders.
The Nucleus Genetics Advantage: Combining ultra-deep NGS target enrichment panels customized for ophthalmic genetics, advanced bioinformatic pipelines, and multidisciplinary curation by medical geneticists and ophthalmologists, we transform complex ocular genomic data into actionable clinical insights.
Get Information About This Service
Our expert team is ready to answer your questions and offer tailored solutions.
Contact Form →